DRKS00033796RecruitingNot Applicable
The burden of recurrence for HR+/HER2- early breast cancer patients (VONKO-018) - VONKOdb Early stage BC 2024
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- ovartis
- Enrollment
- 30,000
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to 120 Years (—)
- Sex
- All
Inclusion Criteria
- •ICD-10 C50
- •- Diagnosis years: 2015-2023
- •- Place of residence in the federal state of the requested registry (population-based cases) at the time of diagnosis
Exclusion Criteria
- •- Cancer case is known to the registry exclusively on the basis of
- •- a death certificate (DCO case)
- •- a pathology report
- •- a progress report
- •- a report on the tumor conference
- •- a combination of the aforementioned reporting types
- •- Previous tumor diagnosis up to 5 years before breast cancer
Investigators
Similar Trials
Recruiting
Phase 1
Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan.male or pre/post-menopausal women age = 18 years with locally advanced/metastatic HR+/HER2-negative BC resistant to ET + CDK4/6 inhibitors. No more than 1 prior systemic chemotherapy or ADC regimens for metastatic disease are permitted.CTIS2023-505385-28-00Solti Group50
Recruiting
Not Applicable
CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast CancerBreast CancerHER2-negative Breast CancerHormone Receptor Positive Breast CarcinomaNCT05870813Institut fuer Frauengesundheit3,000
Recruiting
Not Applicable
HIPEx (HIgh risk ER+HER2- T1-2N0-1 early breast cancer with Palbociclib plus Endocrine Therapy)NeoplasmsKCT0004553Samsung Medical Center578
Not yet recruiting
Phase 2
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Metastatic Breast CancerNCT05577923Fudan University126
Completed
Not Applicable
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of TherapyHR+/HER2- Advanced or Metastatic Breast CancerNCT05853432Novartis Pharmaceuticals157